Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).

HIV medicine - 1 Nov 2009

Scherrer A U, Hasse B, von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Bucher H C, Ledergerber B, Günthard H F

Abstract excerpt

OBJECTIVES: Etravirine (ETV) is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) with reduced cross-resistance to first-generation NNRTIs, which has been primarily studied in randomized clinical trials and not in routine clinical settings. METHODS: ETV resistance-associated mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Multiple, Viral
Share to Nitriles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyridazines

Share to Pyrimidines

Share to Reverse Transcriptase Inhibitors

Share to Switzerland

Share to Treatment Failure

Source

Identifiers

PMID: 19732174
DOI: 10.1111/j.1468-1293.2009.00756.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-19732174-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).PMID 19732174Read ↗

Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018.Semantic proximity Read ↗

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.Semantic proximity Read ↗

Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study CohortSemantic proximity Read ↗

European recommendations for the clinical use of HIV drug resistance testing: 2011 update.Semantic proximity Read ↗

Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011.Semantic proximity Read ↗

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.Semantic proximity Read ↗

RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.Semantic proximity Read ↗

Prevalence of HIV-1 Drug Resistance in Treated PatientsSemantic proximity Read ↗

Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany.Semantic proximity Read ↗

Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.Semantic proximity Read ↗

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.Semantic proximity Read ↗

Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany: the RESINA study 2001-2009.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.